Articles

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between May 19, 2023, and June 20, 2023. Read More ›

Chicago, IL—Interim results from the phase 3 COMMANDS trial demonstrated that first-line treatment with luspatercept-aamt (Reblozyl) increased hemoglobin levels and enabled nearly twice as many patients with transfusion-dependent, lower-risk myelodysplastic syndromes (MDS) to avoid red blood cell transfusions during the first 24 weeks of the study compared with standard-of-care epoetin alfa. Read More ›

Chicago, IL—The presidential theme for the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting was “Partnering With Patients: The Cornerstone of Clinical Care and Research.” In his address during the opening session of the meeting, Eric P. Winer, MD, FASCO, ASCO’s 2022-2023 President, discussed the importance of physician–patient partnerships for improving healthcare outcomes. Read More ›

Chicago, IL—The addition of the PD-1 inhibitor pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) resulted in a substantial and clinically meaningful improvement in overall survival (OS) in patients with persistent, recurrent, or metastatic cervical cancer, according to the final OS analysis of the phase 3 KEYNOTE-826 trial. Read More ›

Chicago, IL—The addition of the CDK4/6 inhibitor ribociclib (Kisqali) to endocrine therapy significantly improved invasive disease-free survival in patients with hormone receptor (HR)-positive, HER2-negative, early breast cancer, according to interim results from the phase 3 NATALEE trial, which were presented at the 2023 American Society of Clinical Oncology Annual Meeting. Read More ›

Nutrition is of growing interest to patients as part of a holistic approach to their cancer care and is an important topic for patients and caregivers to consider following a cholangiocarcinoma (CCA) diagnosis. At the 10th Annual Cholangiocarcinoma Foundation Conference, Stephanie Roit, MS, RD, CDN, CSO, Outpatient Oncology Dietitian, New York-Presbyterian Hospital, New York City, and caregiver Anita Benson highlighted important considerations and personal experiences with proper nutrition in managing patients with CCA. Read More ›

Updated results from a large clinical trial confirm that, for some patients with bladder cancer that can be removed with surgery, receiving immunotherapy immediately afterwards is an effective treatment. Read More ›

Artificial intelligence (AI)-powered medical treatment options are on the rise and have the potential to improve diagnostic accuracy, but a new study led by University of Arizona Health Sciences researchers found that approximately 52% of participants would choose a human doctor rather than AI for diagnosis and treatment. Read More ›

Alexandria, VA—In the Prevent Cancer Foundation’s first annual Early Detection Survey, 65% of Americans aged ≥21 years say they are not up to date with one or more routine cancer screenings. Read More ›

Analysis of the long-term results of the CodeBreak 100 clinical trial showed that sotorasib demonstrated long-term efficacy, in particular among patients with low initial circulating tumor DNA values. Read More ›